Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 7, 2011

EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS

  • The European regulatory authorities approved Biogen Idec’s single-use intramuscular autoinjector, Avonex PEN, for patients with relapsing multiple sclerosis and those who have had a single demyelinating event. The prefilled, once-a-week Avonex-based product integrates the previously approved Avonex prefilled syringe with a shorter needle.  

    Clearance in the EU was based on data from an open-label Phase IIIb study in which patients previously using the Avonex prefilled syringe were switched to the new Avonex PEN device. The overall success rate for patients using Avonex PEN was 89%, and 94% of patients expressed a preference for the device over the Avonex prefilled syringe.  



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »